Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikulaa Parachuri

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Eye (London, England)|April 23, 2020
Brolucizumab-another anti-VEGF or beyondAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|April 7, 2020
Brolucizumab and immunogenicityAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|August 30, 2023
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?Ashish Sharma, Anat Loewenstein, Nikulaa Parachuri, et al.
Ophthalmology. Retina|August 28, 2019
Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be ExploredAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|October 21, 2020
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real worldAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|March 6, 2020
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|August 10, 2021
Semaglutide and the risk of diabetic retinopathy-current perspectiveAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|October 31, 2021
Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trialsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
The British Journal of Ophthalmology|December 9, 2020
Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolationAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|September 16, 2022
Approved biosimilar ranibizumab-a global updateAshish Sharma, Mineo Kondo, Chiharu Iwahashi, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Eye (London, England)|April 23, 2020
Brolucizumab-another anti-VEGF or beyondAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|April 7, 2020
Brolucizumab and immunogenicityAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|August 30, 2023
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?Ashish Sharma, Anat Loewenstein, Nikulaa Parachuri, et al.
Ophthalmology. Retina|August 28, 2019
Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be ExploredAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|October 21, 2020
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real worldAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|March 6, 2020
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|August 10, 2021
Semaglutide and the risk of diabetic retinopathy-current perspectiveAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|October 31, 2021
Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trialsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
The British Journal of Ophthalmology|December 9, 2020
Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolationAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|September 16, 2022
Approved biosimilar ranibizumab-a global updateAshish Sharma, Mineo Kondo, Chiharu Iwahashi, et al.
Pageof 7